Skip to search formSkip to main contentSkip to account menu

gadoterate meglumine

A gadolinium chelate paramagnetic contrast agent. When placed in a magnetic field, gadoterate meglumine produces a large magnetic moment and so a… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
The invention relates to contrast agents for magnetic resonance imaging technologies, in particular to a method for purifying… 
2014
2014
Any information contained in this pdf file is automatically generated from digital material submitted to EPOS by third parties in… 
2014
2014
Poster: "ECR 2014 / C-2023 / Contrast-enhanced MRA of the peripheral arteries at 3T: comparison of SNR and CNR between gadoterate… 
2013
2013
The invention, as meglumine go relates to a process for the preparation of a contrast agent composition comprising a etherate… 
2013
2013
Poster: "ECR 2014 / C-0895 / Comparison between 0.1 mmol/kg of gadoterate meglumine and 0.075 of gadobenate dimeglumine in brain… 
2012
2012
PurposeThe aim of this study was to compare low-dose imaging with gadobutrol and gadoterate meglumine (Gd-DOTA) for evaluation of… 
2012
2012
gadoterate meglumine-MRA to gadobutrol-MRA with DSA Michael Lell, Javier Arnaiz, Denis Krause, Luis Marti-Bonmati, Manuela… 
2009
2009
4 , data not shown). The CA concentration in the brain that resulted in the highest SNR (~ 40:1) was 2.5 mM gadoterate meglumine… 
1995
1995
Magnetic resonance imaging contrast agents (CAg) such as the gadolinium complexes are more and more used for diagnosis and raise… 
1993
1993
To evaluate the safety and efficacy of a gadoterate meglumine formulation as an oral contrast agent, MRI (0.5 T) was performed on…